NOTE: This order is nonprecedential.

United States Court of Appeals for the Federal Circuit

ABBVIE BIOTECHNOLOGY, LTD.,
Appellant

v.

UNITED STATES, ANDREI IANCU, Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office,
Intervenors

2017-2304, 2017-2305, 2017-2306

Appeals from the United States Patent and Trademark Office, Patent Trial and Appeal Board in Nos. IPR2016-00172, IPR2016-00188, and IPR2016-00189.

- -

ABBVIE BIOTECHNOLOGY, LTD.,
Appellant

v.

BOEHRINGER INGELHEIM INTERNATIONAL GMBH, BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.,
Appellees

UNITED STATES,
Intervenor

2017-2362, 2017-2363

Appeals from the United States Patent and Trademark Office, Patent Trial and Appeal Board in Nos. IPR2016-00408 and IPR2016-00409.

O R D E R

Upon notification from the Director of the United States Patent and Trademark Office that, pursuant to 35 U.S.C. § 143, he intervenes in the above captioned appeal,

IT IS ORDERED THAT:

(1) The Director is added as an intervenor to Appeal Nos. 2017-2304, 2017-2305, and 2017-2306. The revised official caption for the consolidated appeals is reflected above.

(2) As per the order issued on January 31, 2019, the Director's and United States' intervenor briefs are due within 40 days of notification of the Director's election. To the extent the Director or the United States relies on portions of the record that are not already contained in the joint appendix, they must submit a separate appendix containing those portions of the record at the time they file their respective briefs. AbbVie Biotechnology, Ltd. may file its reply brief within 14 days of the later of the dates of filing of the Director's brief and the United States' brief.

(3) Principal counsel for the Director must promptly file an entry of appearance and docketing statement.

FOR THE COURT

March 08, 2019
Date

/s/Peter R. Marksteiner
Peter R. Marksteiner
Clerk of Court